Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

BACKGROUND: The epidermal growth factor receptor (EGFR) is an established target for anti-cancer treatment in different tumour types. Two different strategies have been explored to inhibit this pivotal molecule in epithelial cancer development: small molecules TKIs and monoclonal antibodies. ErbB/HE...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cavazzoni, Andrea, Alfieri, Roberta R, Cretella, Daniele, Saccani, Francesca, Ampollini, Luca, Galetti, Maricla, Quaini, Federico, Graiani, Gallia, Madeddu, Denise, Mozzoni, Paola, Galvani, Elena, La Monica, Silvia, Bonelli, Mara, Fumarola, Claudia, Mutti, Antonio, Carbognani, Paolo, Tiseo, Marcello, Barocelli, Elisabetta, Petronini, Pier Giorgio, Ardizzoni, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577499/
https://ncbi.nlm.nih.gov/pubmed/23234355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-91
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados